Most Influential NEJM Papers (2025-09 Version)
The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society. It is among the most prestigious peer-reviewed medical journals as well as the oldest continuously published one. Paper Digest Team analyze all papers published on NEJM in the past years, and presents the 10 most influential papers for each year (based on when the paper became available online). This ranking list is automatically constructed based upon citations from both research papers and granted patents, and will be frequently updated to reflect the most recent changes. To find the most influential papers from other conferences/journals, visit Best Paper Digest page. Note: the most influential papers may or may not include the papers that won the best paper awards. (Version: 2025-09)
This list is created by the Paper Digest Team. Experience the cutting-edge capabilities of Paper Digest, an innovative AI-powered research platform that empowers you to read articles, write articles, get answers, conduct literature reviews and generate research reports.
Paper Digest Team
New York City, New York, 10017
team@paperdigest.org
TABLE 1: Most Influential NEJM Papers (2025-09 Version)
| Year | Rank | Paper | Author(s) |
|---|---|---|---|
| 2025 | 1 | Asundexian Versus Apixaban in Patients with Atrial Fibrillation IF:3 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Marcel Benkhoff; Philipp Mourikis; Amin Polzin; |
| 2025 | 2 | Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes IF:3 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An … |
DARREN K MCGUIRE et. al. |
| 2025 | 3 | Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer IF:3 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to … |
JENS HOEPPNER et. al. |
| 2025 | 4 | Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis IF:3 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In this ongoing phase 3, … |
ARUN J SANYAL et. al. |
| 2025 | 5 | Sepsis and Septic Shock IF:3 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Nuala J Meyer; Hallie C Prescott; |
| 2025 | 6 | Abelacimab Versus Rivaroxaban in Patients with Atrial Fibrillation IF:3 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral … |
CHRISTIAN T RUFF et. al. |
| 2025 | 7 | Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion IF:3 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a … |
MAYANK GOYAL et. al. |
| 2025 | 8 | Tirzepatide As Compared with Semaglutide for The Treatment of Obesity IF:3 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but … |
LOUIS J ARONNE et. al. |
| 2024 | 1 | A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis IF:7 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective … |
STEPHEN A HARRISON et. al. |
| 2024 | 2 | Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would mitigate … |
VLADO PERKOVIC et. al. |
| 2024 | 3 | Microplastics and Nanoplastics in Atheromas and Cardiovascular Events IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Microplastics and nanoplastics (MNPs) are emerging as a potential risk factor for cardiovascular disease in preclinical studies. Direct evidence that this risk extends to humans … |
RAFFAELE MARFELLA et. al. |
| 2024 | 4 | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. We … |
THOMAS POWLES et. al. |
| 2024 | 5 | CD19 CAR T-Cell Therapy in Autoimmune Disease – A Case Series with Follow-up IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term immune suppression. … |
FABIAN MÜLLER et. al. |
| 2024 | 6 | Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated … |
JACOB E MØLLER et. al. |
| 2024 | 7 | Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis IF:5 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of … |
ROHIT LOOMBA et. al. |
| 2024 | 8 | Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction IF:5 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with … |
SCOTT D SOLOMON et. al. |
| 2024 | 9 | Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes IF:4 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies … |
MIKHAIL N KOSIBOROD et. al. |
| 2024 | 10 | Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity IF:4 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like … |
MILTON PACKER et. al. |
| 2023 | 1 | Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes IF:7 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can … |
A MICHAEL LINCOFF et. al. |
| 2023 | 2 | Benefits, Limits, and Risks of GPT-4 As An AI Chatbot for Medicine IF:7 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Peter Lee; Sebastien Bubeck; Joseph Petro; |
| 2023 | 3 | Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity IF:7 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with … |
MIKHAIL N KOSIBOROD et. al. |
| 2023 | 4 | Artificial Intelligence and Machine Learning in Clinical Medicine, 2023 IF:6 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Charlotte J Haug; Jeffrey M Drazen; |
| 2023 | 5 | Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain. … |
BEATE KAMPMANN et. al. |
| 2023 | 6 | Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; … |
STEVEN E NISSEN et. al. |
| 2023 | 7 | Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The role of endovascular therapy for acute stroke with a large infarction has not been extensively studied in differing populations. We conducted a multicenter, prospective, … |
XIAOCHUAN HUO et. al. |
| 2023 | 8 | Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition … |
HEATHER WAKELEE et. al. |
| 2023 | 9 | Trial of Endovascular Thrombectomy for Large Ischemic Strokes IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Trials of the efficacy and safety of endovascular thrombectomy in patients with large ischemic strokes have been carried out in limited populations. We performed a prospective, … |
AMROU SARRAJ et. al. |
| 2023 | 10 | Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer IF:6 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in … |
MANSOOR R MIRZA et. al. |
| 2022 | 1 | Lecanemab in Early Alzheimer’s Disease IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 … |
CHRISTOPHER H VAN DYCK et. al. |
| 2022 | 2 | Covid-19 Vaccine Effectiveness Against The Omicron (B.1.1.529) Variant IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated … |
NICK ANDREWS et. al. |
| 2022 | 3 | Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M ) inhibitor with potent pan-human-coronavirus activity in vitro. We … |
JENNIFER HAMMOND et. al. |
| 2022 | 4 | Tirzepatide Once Weekly for The Treatment of Obesity IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic … |
ANIA M JASTREBOFF et. al. |
| 2022 | 5 | Monkeypox Virus Infection in Humans Across 16 Countries – April-June 2022 IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Before April 2022, monkeypox virus infection in humans was seldom reported outside African regions where it is endemic. Currently, cases are occurring worldwide. Transmission, … |
JOHN P THORNHILL et. al. |
| 2022 | 6 | Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based … |
PATRICK M FORDE et. al. |
| 2022 | 7 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be … |
SHANU MODI et. al. |
| 2022 | 8 | Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a … |
SCOTT D SOLOMON et. al. |
| 2022 | 9 | Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, … |
HUSSEIN A TAWBI et. al. |
| 2022 | 10 | Empagliflozin in Patients with Chronic Kidney Disease IF:7 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess … |
WILLIAM G HERRINGTON et. al. |
| 2021 | 1 | Empagliflozin in Heart Failure with A Preserved Ejection Fraction IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in … |
STEFAN D ANKER et. al. |
| 2021 | 2 | Effectiveness of Covid-19 Vaccines Against The B.1.617.2 (Delta) Variant IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a … |
JAMIE LOPEZ BERNAL et. al. |
| 2021 | 3 | New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Current equations for estimated glomerular filtration rate (eGFR) that use serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR. However, race in … |
LESLEY A INKER et. al. |
| 2021 | 4 | BNT162b2 MRNA Covid-19 Vaccine in A Nationwide Mass Vaccination Setting IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse … |
NOA DAGAN et. al. |
| 2021 | 5 | Once-Weekly Semaglutide in Adults with Overweight or Obesity IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an … |
JOHN P H WILDING et. al. |
| 2021 | 6 | Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine Against Covid-19 IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) … |
JERALD SADOFF et. al. |
| 2021 | 7 | Thrombotic Thrombocytopenia After ChAdOx1 NCov-19 Vaccination IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of … |
ANDREAS GREINACHER et. al. |
| 2021 | 8 | Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine Over 6 Months IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in … |
EINAV G LEVIN et. al. |
| 2021 | 9 | Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. We evaluated tocilizumab and sarilumab in an … |
ANTHONY C GORDON et. al. |
| 2021 | 10 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with … |
NIKHIL C MUNSHI et. al. |
| 2020 | 1 | A Novel Coronavirus from Patients with Pneumonia in China, 2019 IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was … |
NA ZHU et. al. |
| 2020 | 2 | Clinical Characteristics of Coronavirus Disease 2019 in China IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of … |
WEI-JIE GUAN et. al. |
| 2020 | 3 | Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The initial cases of novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019 and January 2020. We analyzed data on the … |
QUN LI et. al. |
| 2020 | 4 | Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background The initial cases of novel coronavirus (2019-nCoV)–infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019 and January 2020. We analyzed … |
QUN LI et. al. |
| 2020 | 5 | Safety and Efficacy of The BNT162b2 MRNA Covid-19 Vaccine IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a … |
FERNANDO P POLACK et. al. |
| 2020 | 6 | Aerosol and Surface Stability of SARS-CoV-2 As Compared with SARS-CoV-1 IF:9 Related Papers Related Patents Related Grants Related Venues Related Experts View |
NEELTJE VAN DOREMALEN et. al. |
| 2020 | 7 | Efficacy and Safety of The MRNA-1273 SARS-CoV-2 Vaccine IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid … |
LINDSEY R BADEN et. al. |
| 2020 | 8 | First Case of 2019 Novel Coronavirus in The United States IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV … |
MICHELLE L HOLSHUE et. al. |
| 2020 | 9 | Remdesivir for The Treatment of Covid-19 — Final Report IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be … |
J. BEIGEL et. al. |
| 2020 | 10 | A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. We conducted a randomized, controlled, open-label trial involving … |
BIN CAO et. al. |
| 2019 | 1 | Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through … |
JOHN J V MCMURRAY et. al. |
| 2019 | 2 | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of … |
VLADO PERKOVIC et. al. |
| 2019 | 3 | Transcatheter Aortic‐Valve Replacement with A Balloon‐Expandable Valve in Low‐Risk Patients IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND Among patients with aortic stenosis who are at intermediate or high risk for death with surgery, major outcomes are similar with transcatheter aortic‐valve replacement … |
M. MACK et. al. |
| 2019 | 4 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor … |
S. SCHUSTER et. al. |
| 2019 | 5 | Five-Year Survival With Combined Nivolumab And Ipilimumab In Advanced Melanoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. … |
JAMES LARKIN et. al. |
| 2019 | 6 | Transcatheter Aortic‐Valve Replacement with A Self‐Expanding Valve in Low‐Risk Patients IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND Transcatheter aortic‐valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis who are at increased risk for death from surgery; … |
J. POPMA et. al. |
| 2019 | 7 | Pembrolizumab Plus Axitinib Versus Sunitinib for Advanced Renal‐Cell Carcinoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal‐cell carcinoma. … |
B. RINI et. al. |
| 2019 | 8 | Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab … |
MATTHEW D HELLMANN et. al. |
| 2019 | 9 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both … |
SURESH S RAMALINGAM et. al. |
| 2019 | 10 | Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal‐Cell Carcinoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND In a single‐group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal‐cell carcinoma. This phase 3 trial involving … |
R. MOTZER et. al. |
| 2018 | 1 | Pembrolizumab Plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor … |
L. GANDHI et. al. |
| 2018 | 2 | Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is … |
STEPHEN D WIVIOTT et. al. |
| 2018 | 3 | Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background In a single‐center phase 1–2a study, the anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel produced high rates of complete remission and was … |
S. MAUDE et. al. |
| 2018 | 4 | Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background Osimertinib is an oral, third‐generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) that selectively inhibits both … |
J. SORIA et. al. |
| 2018 | 5 | Thrombectomy For Stroke At 6 To 16 Hours With Selection By Perfusion Imaging IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Thrombectomy is currently recommended for eligible patients with stroke who are treated within 6 hours after the onset of symptoms. We conducted a multicenter, randomized, … |
GREGORY W ALBERS et. al. |
| 2018 | 6 | Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal‐Cell Carcinoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND Nivolumab plus ipilimumab produced objective responses in patients with advanced renal‐cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus … |
R. MOTZER et. al. |
| 2018 | 7 | Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Side Effects of Immune Checkpoint Blockade The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and … |
M. Postow; R. Sidlow; M. Hellmann; |
| 2018 | 8 | Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND The cancer‐cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. This … |
M. SOCINSKI et. al. |
| 2018 | 9 | Pembrolizumab Plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background Standard first‐line therapy for metastatic, squamous non–small‐cell lung cancer (NSCLC) is platinum‐based chemotherapy or pembrolizumab (for patients with programmed … |
L. PAZ-ARES et. al. |
| 2018 | 10 | Nivolumab Plus Ipilimumab in Lung Cancer with A High Tumor Mutational Burden IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a … |
MATTHEW D HELLMANN et. al. |
| 2017 | 1 | Antiinflammatory Therapy With Canakinumab For Atherosclerotic Disease IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of … |
PAUL M RIDKER et. al. |
| 2017 | 2 | Semaglutide And Cardiovascular Outcomes In Patients With Type 2 Diabetes IF:8 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Steven P Marso; Anders G Holst; Tina Vilsbøll; |
| 2017 | 3 | Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by … |
MARC S SABATINE et. al. |
| 2017 | 4 | Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background In a phase 1 trial, axicabtagene ciloleucel (axi‐cel), an autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy, showed efficacy in patients with … |
S. NEELAPU et. al. |
| 2017 | 5 | Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We … |
BRUCE NEAL et. al. |
| 2017 | 6 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients … |
JEDD D WOLCHOK et. al. |
| 2017 | 7 | Pembrolizumab As Second‐Line Therapy for Advanced Urothelial Carcinoma IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Background Patients with advanced urothelial carcinoma that progresses after platinum‐based chemotherapy have a poor prognosis and limited treatment options. Methods In this … |
J. BELLMUNT et. al. |
| 2017 | 8 | Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: BACKGROUND Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) that is selective for both EGFR‐TKI sensitizing and T790M resistance mutations … |
T. MOK et. al. |
| 2017 | 9 | Diabetic Foot Ulcers and Their Recurrence IF:8 Related Papers Related Patents Related Grants Related Venues Related Experts View |
David G Armstrong; Andrew J M Boulton; Sicco A Bus; |
| 2017 | 10 | Tumor Mutational Burden And Response Rate To PD-1 Inhibition IF:9 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee; |
| 2016 | 1 | Pembrolizumab Versus Chemotherapy For PD-L1-Positive Non-Small-Cell Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased … |
MARTIN RECK et. al. |
| 2016 | 2 | Liraglutide And Cardiovascular Outcomes In Type 2 Diabetes IF:8 Related Papers Related Patents Related Grants Related Venues Related Experts View |
John B Buse; |
| 2016 | 3 | Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular … |
STEVEN P MARSO et. al. |
| 2016 | 4 | Transcatheter Or Surgical Aortic-Valve Replacement In Intermediate-Risk Patients IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical … |
MARTIN B LEON et. al. |
| 2016 | 5 | Genomic Classification and Prognosis in Acute Myeloid Leukemia IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines … |
ELLI PAPAEMMANUIL et. al. |
| 2016 | 6 | Empagliflozin And Progression Of Kidney Disease In Type 2 Diabetes IF:9 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Christoph Wanner; Silvio E Inzucchi; Bernard Zinman; |
| 2016 | 7 | Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients … |
TONY S MOK et. al. |
| 2016 | 8 | Body Fatness and Cancer–Viewpoint of The IARC Working Group IF:8 Related Papers Related Patents Related Grants Related Venues Related Experts View |
BÉATRICE LAUBY-SECRETAN et. al. |
| 2016 | 9 | The Human Intestinal Microbiome In Health And Disease IF:8 Related Papers Related Patents Related Grants Related Venues Related Experts View |
Susan V Lynch; Oluf Pedersen; |
| 2016 | 10 | Mutations Associated With Acquired Resistance To PD-1 Blockade In Melanoma IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted … |
JESSE M ZARETSKY et. al. |
| 2015 | 1 | Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. In this … |
HOSSEIN BORGHAEI et. al. |
| 2015 | 2 | Nivolumab Versus Docetaxel In Advanced Squamous-Cell Non-Small-Cell Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This … |
JULIE BRAHMER et. al. |
| 2015 | 3 | Empagliflozin, Cardiovascular Outcomes, And Mortality In Type 2 Diabetes IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 … |
BERNARD ZINMAN et. al. |
| 2015 | 4 | Pembrolizumab For The Treatment Of Non-small-cell Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 … |
EDWARD B GARON et. al. |
| 2015 | 5 | Pembrolizumab Versus Ipilimumab In Advanced Melanoma IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune … |
CAROLINE ROBERT et. al. |
| 2015 | 6 | Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with … |
ROBERT J MOTZER et. al. |
| 2015 | 7 | Randomized Assessment Of Rapid Endovascular Treatment Of Ischemic Stroke IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% of patients die within 90 days after stroke onset or do not regain functional independence … |
MAYANK GOYAL et. al. |
| 2015 | 8 | Endovascular Therapy For Ischemic Stroke With Perfusion-imaging Selection IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Trials of endovascular therapy for ischemic stroke have produced variable results. We conducted this study to test whether more advanced imaging selection, recently developed … |
BRUCE C V CAMPBELL et. al. |
| 2015 | 9 | PD-1 Blockade In Tumors With Mismatch-Repair Deficiency IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Somatic mutations have the potential to encode non-self immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects … |
DUNG T LE et. al. |
| 2015 | 10 | Stent-retriever Thrombectomy After Intravenous T-PA Vs. T-PA Alone In Stroke IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Among patients with acute ischemic stroke due to occlusions in the proximal anterior intracranial circulation, less than 40% regain functional independence when treated with … |
JEFFREY L SAVER et. al. |
| 2014 | 1 | A Randomized Trial Of Intraarterial Treatment For Acute Ischemic Stroke IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: In patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion, intraarterial treatment is highly effective for emergency revascularization. However, … |
OLVERT A BERKHEMER et. al. |
| 2014 | 2 | Angiotensin-neprilysin Inhibition Versus Enalapril in Heart Failure IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril … |
JOHN J V MCMURRAY et. al. |
| 2014 | 3 | Nivolumab In Previously Untreated Melanoma Without BRAF Mutation IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of … |
CAROLINE ROBERT et. al. |
| 2014 | 4 | Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may … |
SHANNON L MAUDE et. al. |
| 2014 | 5 | Genetic Basis For Clinical Response To CTLA-4 Blockade In Melanoma IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against … |
ALEXANDRA SNYDER et. al. |
| 2014 | 6 | Age-related Clonal Hematopoiesis Associated with Adverse Outcomes IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would … |
SIDDHARTHA JAISWAL et. al. |
| 2014 | 7 | PD-1 Blockade With Nivolumab In Relapsed Or Refractory Hodgkin’s Lymphoma IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin’s lymphoma, alterations in … |
STEPHEN M ANSELL et. al. |
| 2014 | 8 | Multistate Point-prevalence Survey of Health Care-associated Infections IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Currently, no single U.S. surveillance system can provide estimates of the burden of all types of health care-associated infections across acute care patient populations. We … |
SHELLEY S MAGILL et. al. |
| 2014 | 9 | First-line Crizotinib Versus Chemotherapy In ALK-positive Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is … |
BENJAMIN J SOLOMON et. al. |
| 2014 | 10 | Clonal Hematopoiesis and Blood-cancer Risk Inferred from Blood DNA Sequence IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically … |
GIULIO GENOVESE et. al. |
| 2013 | 1 | Increased Survival in Pancreatic Cancer with Nab-paclitaxel Plus Gemcitabine IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We … |
DANIEL D VON HOFF et. al. |
| 2013 | 2 | Edoxaban Versus Warfarin in Patients with Atrial Fibrillation IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial … |
ROBERT P GIUGLIANO et. al. |
| 2013 | 3 | Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not … |
TIMOTHY J LEY et. al. |
| 2013 | 4 | Nivolumab Plus Ipilimumab in Advanced Melanoma IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the … |
JEDD D WOLCHOK et. al. |
| 2013 | 5 | Safety and Tumor Responses with Lambrolizumab (anti-PD-1) in Melanoma IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody … |
OMID HAMID et. al. |
| 2013 | 6 | Duodenal Infusion Of Donor Feces For Recurrent Clostridium Difficile IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. We studied the effect of duodenal infusion of donor feces in … |
ELS VAN NOOD et. al. |
| 2013 | 7 | Primary Prevention Of Cardiovascular Disease With A Mediterranean Diet IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a … |
RAMÓN ESTRUCH et. al. |
| 2013 | 8 | Chimeric Antigen Receptor-modified T Cells for Acute Lymphoid Leukemia IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established … |
STEPHAN A GRUPP et. al. |
| 2013 | 9 | Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Radiotherapy for breast cancer often involves some incidental exposure of the heart to ionizing radiation. The effect of this exposure on the subsequent risk of ischemic heart … |
SARAH C DARBY et. al. |
| 2013 | 10 | Crizotinib Versus Chemotherapy In Advanced ALK-positive Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral … |
ALICE T SHAW et. al. |
| 2012 | 1 | Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an … |
SUZANNE L TOPALIAN et. al. |
| 2012 | 2 | Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host’s immune … |
JULIE R BRAHMER et. al. |
| 2012 | 3 | Intratumor Heterogeneity and Branched Evolution Revealed By Multiregion Sequencing IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. To examine … |
MARCO GERLINGER et. al. |
| 2012 | 4 | Isolation Of A Novel Coronavirus From A Man With Pneumonia In Saudi Arabia IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: A previously unknown coronavirus was isolated from the sputum of a 60-year-old man who presented with acute pneumonia and subsequent renal failure with a fatal outcome in Saudi … |
Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier; |
| 2012 | 5 | Preoperative Chemoradiotherapy For Esophageal Or Junctional Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy … |
P VAN HAGEN et. al. |
| 2012 | 6 | Increased Survival with Enzalutamide in Prostate Cancer After Chemotherapy IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether … |
HOWARD I SCHER et. al. |
| 2012 | 7 | Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Estimates of glomerular filtration rate (GFR) that are based on serum creatinine are routinely used; however, they are imprecise, potentially leading to the overdiagnosis of … |
LESLEY A INKER et. al. |
| 2012 | 8 | Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The order and magnitude of pathologic processes in Alzheimer’s disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer’s … |
RANDALL J BATEMAN et. al. |
| 2012 | 9 | Trastuzumab Emtansine for HER2-positive Advanced Breast Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the … |
SUNIL VERMA et. al. |
| 2012 | 10 | Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. We conducted a … |
JARED M BAETEN et. al. |
| 2011 | 1 | Improved Survival With Vemurafenib In Melanoma With BRAF V600E Mutation IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF … |
PAUL B CHAPMAN et. al. |
| 2011 | 2 | FOLFIRINOX Versus Gemcitabine For Metastatic Pancreatic Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with … |
THIERRY CONROY et. al. |
| 2011 | 3 | Transcatheter Versus Surgical Aortic-valve Replacement In High-risk Patients IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The use of transcatheter aortic-valve replacement has been shown to reduce mortality among high-risk patients with aortic stenosis who are not candidates for surgical replacement. … |
CRAIG R SMITH et. al. |
| 2011 | 4 | Rivaroxaban Versus Warfarin In Nonvalvular Atrial Fibrillation IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa … |
MANESH R PATEL et. al. |
| 2011 | 5 | Ipilimumab Plus Dacarbazine For Previously Untreated Metastatic Melanoma IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with … |
CAROLINE ROBERT et. al. |
| 2011 | 6 | Abiraterone And Increased Survival In Metastatic Prostate Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen … |
JOHANN S DE BONO et. al. |
| 2011 | 7 | Apixaban Versus Warfarin In Patients With Atrial Fibrillation IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa … |
CHRISTOPHER B GRANGER et. al. |
| 2011 | 8 | Chimeric Antigen Receptor-modified T Cells In Chronic Lymphoid Leukemia IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells … |
David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June; |
| 2011 | 9 | A Prospective Natural-history Study Of Coronary Atherosclerosis IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Atherosclerotic plaques that lead to acute coronary syndromes often occur at sites of angiographically mild coronary-artery stenosis. Lesion-related risk factors for such events … |
GREGG W STONE et. al. |
| 2011 | 10 | Everolimus in Postmenopausal Hormone-receptor-positive Advanced Breast Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the … |
JOSÉ BASELGA et. al. |
| 2010 | 1 | Improved Survival With Ipilimumab In Patients With Metastatic Melanoma IF:10 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab–which blocks cytotoxic … |
F STEPHEN HODI et. al. |
| 2010 | 2 | Transcatheter Aortic-valve Implantation For Aortic Stenosis In Patients Who Cannot Undergo Surgery IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Many patients with severe aortic stenosis and coexisting conditions are not candidates for surgical replacement of the aortic valve. Recently, transcatheter aortic-valve … |
MARTIN B LEON et. al. |
| 2010 | 3 | Early Palliative Care For Patients With Metastatic Non-small-cell Lung Cancer IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may receive aggressive care at the end of life. We examined the effect of introducing … |
JENNIFER S TEMEL et. al. |
| 2010 | 4 | Human Papillomavirus And Survival Of Patients With Oropharyngeal Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status … |
K KIAN ANG et. al. |
| 2010 | 5 | Sipuleucel-T Immunotherapy For Castration-resistant Prostate Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate … |
PHILIP W KANTOFF et. al. |
| 2010 | 6 | Preexposure Chemoprophylaxis For HIV Prevention In Men Who Have Sex With Men IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. We randomly assigned 2499 … |
ROBERT M GRANT et. al. |
| 2010 | 7 | Anaplastic Lymphoma Kinase Inhibition In Non-small-cell Lung Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We … |
EUNICE L KWAK et. al. |
| 2010 | 8 | Inhibition Of Mutated, Activated BRAF In Metastatic Melanoma IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test … |
KEITH T FLAHERTY et. al. |
| 2010 | 9 | Cisplatin Plus Gemcitabine Versus Gemcitabine For Biliary Tract Cancer IF:9 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study involving … |
JUAN VALLE et. al. |
| 2010 | 10 | Infliximab, Azathioprine, Or Combination Therapy For Crohn’s Disease IF:8 Summary Related Papers Related Patents Related Grants Related Venues Related Experts View Abstract: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn’s disease are unknown. In this randomized, double-blind trial, we … |
JEAN FRÉDÉRIC COLOMBEL et. al. |